BioTuesdays

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

NLS-Pharmaceutics-Logo

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

Heat Biologics

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

Angion-Logo

Stifel starts Angion Biomedica at buy; PT $40

Stifel launched coverage of Angion Biomedica (NASDAQ:ANGN) with a “buy” rating and $40 price target. The stock closed at $19.92 on March 1. Angion’s lead asset, ANG-3777, is a mimetic of hepatocyte growth factor (HGF)...

Pharvaris-Logo

SVB Leerink starts Pharvaris at OP; PT $50

SVB Leerink initiated coverage of Pharvaris B.V. (NASDAQ:PHVS) with an “outperform” rating and $50 price target. The stock closed at $39.23 on March 1. Pharvaris is developing therapies for rare diseases, with a focus...

Avita Medical

Piper starts Avita Medical at OW; PT $27

Piper Sandler launched coverage of Avita Medical (NASDAQ:RCEL) with an “overweight” rating and $27 price target. The stock closed at $21.49 on March 1. Avita makes Recell, which uses a patient’s own skin to make a cell...

Lucira-Health-Logo

WB starts Lucira Health at OP

William Blair initiated coverage of Lucira Health (NASDAQ:LHDX) with an “outperform” rating, based on “our outlook for a series of positive catalysts on commercialization and manufacturing as well as what we believe is...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.